Sildenafil Tablet, Film Coated
Product Images NDC 72789-098

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 72789-098). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789098 Label (72789098)

Sildenafil USP 100 mg film-coated tablets label from PD-Rx Pharmaceuticals, Inc. The label includes a drug warning to keep out of reach of children, directions for dosage, product identification, lot number G20C13, and expiration date 11/2021. The packaging indicates a supply of 10 tablets. Manufacturer details and barcode are also present on the label.*

FDA Label Image

Sildenafilfigure7 (Sildenafilfigure7)

A bar graph depicting the percentage of patients reporting improvement across four treatment groups: Placebo, Sildenafil Citrate 25 mg Tablets, Sildenafil Citrate 50 mg Tablets, and Sildenafil Citrate 100 mg Tablets, with increasing improvement percentages from 24% in placebo to 82% in the 100 mg treatment group.*

FDA Label Image

Sildenafilfigure1 (Sildenafilfigure1)

A line graph comparing systolic blood pressure (mmHg) over 24 hours post-dose between Sildenafil 100 mg and placebo. The x-axis represents time in hours from pre-dose to 24 hours post-dose, and the y-axis shows changes in systolic blood pressure. Data points for both Sildenafil and placebo are plotted with distinct markers, showing trends over time.*

FDA Label Image

Sildenafilfigure2 (Sildenafilfigure2)

A line graph comparing the change in plasma concentration (ng/mL) over time (hours) for Sildenafil 100 mg versus placebo. The graph plots mean values at multiple time points throughout an 8-hour period after dosing, with Sildenafil showing higher plasma levels than placebo.*

FDA Label Image

Sildenafilfigure3 (Sildenafilfigure3)

A line chart depicting changes in a variable over time for two treatment groups: one with Doxazosin - Placebo and the other with Doxazosin - Sildenafil 50 mg. The x-axis represents time postdose in hours, and the y-axis shows the percent change from baseline. The graph includes blue and gray lines with data points marking measurements over an 8-hour period.*

FDA Label Image

Sildenafilfigure4 (Sildenafilfigure4)

A line graph depicting changes in mean arterial pressure over time in hours after dosing. The graph compares two treatments: Doxazosin combined with Sildenafil 100 mg, and Doxazosin combined with placebo. Time after dosing is shown on the horizontal axis, and mean arterial pressure change is shown on the vertical axis.*

FDA Label Image

Sildenafilfigure5 (Sildenafilfigure5)

A line graph displaying plasma concentration (ng/mL) of Sildenafil over time (hours) post dose for the treatment with a commercial tablet. The x-axis represents time in hours up to 24 hours, and the y-axis shows plasma concentration ranging from 0 to 500 ng/mL, with an initial peak around 1 hour, followed by a decline over time.*

FDA Label Image

Sildenafilfigure6a (Sildenafilfigure6a)

A bar chart showing the percentage of patients at endpoint by baseline score. The x-axis represents baseline scores from 0 to 5, and the y-axis represents the percentage of patients. Multiple bars for each score correspond to different categories labeled 0 to 5 in the legend.*

FDA Label Image

Sildenafilfigure6b (Sildenafilfigure6b)

A bar chart showing the percentage of patients at the endpoint for various baseline scores ranging from 0 to 5. Different bars represent categories labeled 00 through 5, with the x-axis indicating baseline scores and the y-axis showing the percentage of patients at the endpoint. The chart compares distributions across baseline score groups.*

FDA Label Image

Sildenafilstructure (Sildenafilstructure)

Chemical structure of Sildenafil depicted with labeled molecular groups, showing the arrangement of atoms and bonds distinctive to this active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.